Latest From X-Chem Inc.
OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.
April had four VC rounds of $100m or more, including Allogene's $300m to develop CAR-T therapies licensed from Pfizer. Innovent Biologics raised $150m, BenevolentAI brought in $115m and Constellation garnered $100m last month.
Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.
In addition to its latest collaboration with Sangamo, Pfizer also teams with Arvinas on protein-degradation therapies. AstraZeneca sells off four mature products to ANI, while Summit enhances its antibiotic capabilities with Discuva buyout and out-licenses Latin American rights to ridinilazole.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- X-Chem Inc.
- Senior Management
Richard Wagner, PhD, Pres. & CEO
Jeffrey Troderman, CFO
Christelle Huguet, PhD, CSO
Ed Coval, PhD, SVP, Corp. & Bus. Dev.
- Contact Info
Phone: (781) 419-6900
100 Beaver St.
Waltham, MA 02453
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.